Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?

Creative Commons License

BAĞCIOĞLU M., Surcel C., Ozcan S., Mirvald C., Karagoz M. A., Karadag M. A., ...Daha Fazla

ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, cilt.89, sa.4, ss.282-286, 2017 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 89 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4081/aiua.2017.4.282
  • Dergi Adı: ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.282-286
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: Androgen deprivation therapy (ADT) is commonly used as a first-line treatment for locally advanced and metastatic prostatic cancer (Pca). There is no consensus about which alternative treatment should be used after the failure of initial ADT. We aimed to investigate the effect of changes in treatment on PSA and testosterone levels.